- Home
- Oncology latest news
Oncology latest news
Below you’ll find the most recent oncology news across Johnson & Johnson.
Janssen Presents New Data Demonstrating the Combination of Niraparib and Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic Progression-Free Survival as a First-Line Therapy in Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
Initial results from Phase 3 MAGNITUDE study, to be featured in a late-breaking oral presentation at ASCO GU, highlight subset of patients with mCRPC most likely to benefit from treatment
New ERLEADA® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Real-world evidence study demonstrates majority of patients with mCSPC achieved over 90 percent decline in PSA by six months after initiation of ERLEADA® Rapid and deep PSA decline is associated with improved health-related quality of life in advanced prostate cancer as shown by separate post-hoc analysis of patient-reported outcomes from Phase 3 SPARTAN and TITAN studies
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Initial results from Phase 3 MAGNITUDE study of niraparib in combination with abiraterone acetate plus prednisone as a first-line therapy in patients with metastatic castration-resistant prostate cancer featured as an oral presentation New data for ERLEADA® (apalutamide) build on more than a decade of experience in prostate cancer; updated clinical trial information for novel drug delivery system TAR-200 plus cetrelimab in early-stage bladder cancer to be presented
News Archive
Looking for more news? Visit the archive to see a full list of oncology updates from the past several years.
More from Johnson & Johnson
Lung cancer: What you need to know about your risk factor—even if you’ve never smoked
Some 20% of people diagnosed with the disease haven’t touched a cigarette. For Healthy Lung Month, scientists who’ve dedicated their research to defeating lung cancer discuss why early detection is so key—and what you can do to protect yourself.
New Year, new vision: Meet a man tasked with investing in what could be the world’s next great medical discoveries
Johnson & Johnson aspires to change the trajectory of health for humanity. And Tom Heyman helps make that lofty goal a reality through his work as the head of Johnson & Johnson’s venture capital division, which invests in dozens of companies each year. He shares what’s on his radar for 2019.
Caring & giving around the globe: 43 Johnson & Johnson programs that are transforming lives—and the future of healthcare
Check out this fun interactive map for a glimpse at how the company is helping people on nearly every continent live healthier lives.